Early Disclosure of Blood‐Based Biomarkers Optimizes Alzheimer's Disease Management and Treatment Initiation: the PLASMAR study
Isabel Estragués‐Gázquez, José Contador, Leidy Dayana Martinez, Aida Fernández‐Lebrero et autres
Abstract Background Blood‐based biomarkers (BBMs) offer a cost‐effective, non‐invasive approach for detecting Alzheimer's disease (AD) pathology, but their impact on improving diagnostic certainty and patient management remains unclear. The PLASMAR study is a prospective, single‐center, blinded, randomized controlled trial assessing the effect …
es (code pays fourni par la source)
0 citations
Alzheimer s & Dementia